Imidazotriazines and imidazopyrimidines as kinase inhibitors
申请人:Incyte Corporation
公开号:US07767675B2
公开(公告)日:2010-08-03
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Imidazotriaines and imidazopyrimidines as kinase inhibitors
申请人:Incyte Corporation
公开号:US10738052B2
公开(公告)日:2020-08-11
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors
申请人:Incyte Corporation
公开号:US20180282340A1
公开(公告)日:2018-10-04
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.